cilostazol has been researched along with carbostyril in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dousa, TP; Grande, JP; Matousovic, K; Tsuboi, Y; Walker, H | 1 |
| Hidaka, H; Inoue, Y; Kihara, Y; Kimura, Y; Koga, Y; Nishi, T; Okada, M; Tachibana, K; Tochizawa, S; Toga, K | 1 |
| Guan, Q; Montrose, DC; Quilley, J; Rajagopalan, S; Smith, CJ; Zhao, H | 1 |
| Adderley, S; Bowles, EA; Hanson, MS; Sprague, RS; Sridharan, M; Stephenson, AH | 1 |
| Hayashi, H; Sudo, T | 1 |
| Hashimoto, K; Ishima, T | 1 |
| Chaitongrat, S; Lertsuwunseri, V; Mahachai, V; Pittayanon, R; Piyachaturawat, P; Prueksapanich, P; Rerknimitr, R; Srimahachota, S | 1 |
1 trial(s) available for cilostazol and carbostyril
| Article | Year |
|---|---|
Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.
Topics: Aged; Alanine; Anti-Ulcer Agents; Aspirin; Cilostazol; Clopidogrel; Cytoprotection; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Peptic Ulcer; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quinolones; Thailand; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
6 other study(ies) available for cilostazol and carbostyril
| Article | Year |
|---|---|
Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cell Division; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Down-Regulation; Folic Acid; Isoenzymes; Kidney Tubules; Male; Phosphodiesterase Inhibitors; Proliferating Cell Nuclear Antigen; Pyrrolidinones; Quinazolines; Quinolones; Rats; Rats, Sprague-Dawley; Rolipram; Signal Transduction; Tetrazoles | 1997 |
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
Topics: Animals; Arteriosclerosis; Cilostazol; Hyperplasia; Platelet Aggregation Inhibitors; Quinolines; Quinolones; Rabbits; Tetrazoles; Thrombosis; Urea | 1998 |
Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angioplasty, Balloon; Animals; Aorta; Carboxylic Acids; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Milrinone; Nitriles; Phosphodiesterase Inhibitors; Phosphorylation; Quinolones; Rats; Rats, Sprague-Dawley; Tetrazoles; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2007 |
Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP.
Topics: Adult; Aged; Animals; Blotting, Western; Cilostazol; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 3; Drug Interactions; Erythrocyte Membrane; Female; Humans; Iloprost; Male; Middle Aged; Milrinone; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Quinolones; Rabbits; Tetrazoles; Up-Regulation | 2008 |
Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets.
Topics: Animals; Binding Sites; Blood Platelets; Cilostazol; Colforsin; Collagen; Cyclic AMP; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; In Vitro Techniques; Isoquinolines; Phosphatidylinositol 3-Kinases; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolones; Rats; Rats, Sprague-Dawley; Serine; Sulfonamides; Tetrazoles | 2009 |
Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol.
Topics: Animals; Cilostazol; Drug Synergism; Inositol 1,4,5-Trisphosphate Receptors; JNK Mitogen-Activated Protein Kinases; Milrinone; Mitogen-Activated Protein Kinase Kinases; Nerve Growth Factor; Neurites; PC12 Cells; Peptide Elongation Factor 1; Phosphatidylinositol 3-Kinases; Phosphodiesterase 3 Inhibitors; Phosphoinositide-3 Kinase Inhibitors; Phospholipase C gamma; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolones; raf Kinases; ras Proteins; Rats; Receptor, trkA; Signal Transduction; Tetrazoles | 2011 |